CG Oncology (NASDAQ:CGON) Director James Mulay Sells 24,165 Shares of Stock

CG Oncology, Inc. (NASDAQ:CGON) Director James Mulay sold 24,165 shares of CG Oncology stock in a transaction on Friday, July 10th. The stock was sold at an average price of $75.16, for a total transaction of $1,816,241.40. Following the transaction, the director owned 24,165 shares in the company, valued at approximately $1,816,241.40. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

James Mulay also recently made the following trade(s):

• On Monday, June 15th, James Mulay sold 1,964 shares of CG Oncology stock. The stock was sold at an average price of $60.12, for a total transaction of $118,075.68.
• On Friday, April 17th, James Mulay sold 15,600 shares of CG Oncology stock. The stock was sold at an average price of $73.01, for a total transaction of $1,138,956.00.

CG Oncology Price Performance

NASDAQ CGON traded down $0.73 on Tuesday, reaching $71.77. The company had a trading volume of 1,107,216 shares, compared to its average volume of 1,197,893. The firm has a market cap of $6.33 billion, a price-to-earnings ratio of -30.80 and a beta of 0.22. CG Oncology, Inc. has a fifty-two week low of $23.65 and a fifty-two week high of $77.00. The business has a 50 day moving average of $65.03 and a two-hundred day moving average of $60.56.

CG Oncology (NASDAQ:CGON) last announced its earnings results on Friday, May 8th. The company reported ($0.71) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.13). The business had revenue of $1.08 million during the quarter, compared to analysts’ expectations of $0.45 million. As a group, research analysts predict that CG Oncology, Inc. will post -2.89 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on CGON shares. JPMorgan Chase & Co. raised their price objective on CG Oncology from $91.00 to $96.00 and gave the stock an “overweight” rating in a research report on Monday, May 11th. HC Wainwright reissued a “buy” rating and set a $100.00 target price on shares of CG Oncology in a research report on Monday, May 18th. Wolfe Research initiated coverage on shares of CG Oncology in a report on Tuesday, May 19th. They set a “peer perform” rating for the company. Royal Bank Of Canada boosted their price target on shares of CG Oncology from $79.00 to $81.00 and gave the stock an “outperform” rating in a research report on Monday, May 11th. Finally, Wall Street Zen lowered shares of CG Oncology from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $81.73.

Institutional Investors Weigh In On CG Oncology

Large investors have recently added to or reduced their stakes in the business. Wellington Management Group LLP grew its stake in CG Oncology by 8.8% during the fourth quarter. Wellington Management Group LLP now owns 5,999,790 shares of the company’s stock worth $249,111,000 after purchasing an additional 487,011 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in CG Oncology by 116.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,443,144 shares of the company’s stock valued at $142,961,000 after buying an additional 1,854,386 shares during the period. State Street Corp boosted its holdings in shares of CG Oncology by 46.4% during the 4th quarter. State Street Corp now owns 2,996,695 shares of the company’s stock worth $124,423,000 after buying an additional 950,028 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in shares of CG Oncology by 15.0% during the 2nd quarter. Alliancebernstein L.P. now owns 2,164,214 shares of the company’s stock worth $56,270,000 after buying an additional 281,637 shares in the last quarter. Finally, RTW Investments LP grew its position in shares of CG Oncology by 18.3% during the 4th quarter. RTW Investments LP now owns 2,012,127 shares of the company’s stock worth $83,544,000 after buying an additional 310,911 shares during the period. Institutional investors and hedge funds own 26.56% of the company’s stock.

CG Oncology Company Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.